Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and obesity. Also known as GLP-1 agonists, these drugs work by mimicking a ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Don’t be persuaded by the abundance of propaganda you see in ads, newspapers, magazines, TV, and the Internet. There is no ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...